Mayo Clinic scientists identify possible new treatment for subset of women with triple-negative breast cancer
Mayo Clinic scientists identify possible new treatment for subset of women with triple-negative breast cancer
Mayo Clinic scientists identify possible new treatment for subset of women with triple-negative breast cancer
Mayo scientists identify the drug estradiol as a possible new treatment for a subset of women with triple-negative breast cancer. The results are published in Proceedings of the National Academies of Sciences.
"Triple-negative breast cancer is a type of breast cancer that lacks the expression of the estrogen-alpha receptor, the progesterone receptor and the type 2 receptor for human epidermal growth factor, known as HER2, and shows high rates of recurrence So far, apart from chemotherapy, there were only a few drugs that seemed to work well for the treatment of this disease, "explains Dr. John Hawse.
In previous studies, Dr. Hawse and his colleagues discovered that a second type of estrogen receptor, known as a beta-estrogen receptor, is expressed in approximately 25 percent of triple-negative breast cancer. In the present study, Dr. Hawse's lab demonstrated that estradiol, a hormone that women naturally produce, effectively inhibits the growth of triple-negative breast cancer with estrogen beta receptor expression.
"It was remarkable the discovery that estradiol, which normally stimulates the growth of cancer cells in tumors with estrogen alpha receptor expression, exerts the opposite effect in triple-negative breast cancer. However, estradiol could only inhibit the growth of triple-negative breast cancer when the beta-estrogen receptor was present, "adds Dr. Hawse.
Dr. Hawse and his colleagues discovered a possible mechanism of the anticancer effect of estradiol. They determined that when estradiol binds to the beta-estrogen receptor in triple-negative breast cancer, it stimulates the expression of a group of proteins called cystatins, which show effects of tumor suppression on nearby and distant cancer cells.
Based on these data, Mayo Clinic scientists and the Translational Breast Cancer Research Consortium will soon open a phase II clinical trial to test the efficacy of estradiol as a treatment for women with triple-negative, metastatic and expression-busting breast cancer. of the alpha estrogen receptor.
"Estradiol has the authorization of the United States Food and Drug Administration (FDA) as a treatment for women with breast cancer, but its use is usually limited to women with cancer positive to the recipient. of estrogen alpha that became resistant to standard therapies. We are excited to study whether estradiol can be redirected as a new triple-negative breast cancer treatment with estrogen beta receptor expression, "explains Dr. Matthew Goetz, a medical oncologist and coinvestigator with Dr. Hawse.
The study was funded by the breast cancer grant awarded to Mayo Clinic (P50 CA116201) by the specialized programs of excellence in research (SPORE), belonging to the National Cancer Institute, and by the Eisenberg Foundation. (Source: Mayo Clinic)
.
!function(f,b,e,v,n,t,s)
{if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s)}(window, document,'script',
'https://connect.facebook.net/en_US/fbevents.js');
fbq('init', '369524843414444');
fbq('track', 'PageView');
.
SOURCE LINK ERESVIRAL.COM https://www.beviral.online
Comentarios
Publicar un comentario